Bristol-Myers Squibb Company (BMY)
5 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)
Bristol-Myers Squibb's price continues to rise due to a confluence of factors, not the least of which is an earnings surprise in Q3 2024. The company's raised guidance for 2024 is also encouraging, as is the FDA's approval for its schizophrenia treatment acquired on buying Karuna Therapeautics earlier this year. Despite a high current P/E ratio, projections for 2025 suggest a massive earnings increase is due, which can potentially double the stock price.
Where Will Bristol Myers Squibb Be in 5 Years?
Investors often look to major pharmaceutical stocks as an area that is likely to provide an anchor for their portfolios. Thanks to their supposedly consistent cash flows, they often appear to be capable of steadily growing in value over time.
Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Jefferies London Healthcare Conference November 19, 2024 4:30 AM ET Company Participants David Elkins - CFO Unidentified Company Representative On to the next fireside chat. And again, thanks, everyone, for your attendance.
Bristol-Myers Squibb: Buy This Bargain Before It's Gone
Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its oncology and neuroscience franchises. So, Yervoy's sales amounted to $642 million in the third quarter of 2024, increasing by 10.9% year-on-year and 1.9% quarter-on-quarter. Moreover, on September 26, 2024, the company announced the long-awaited approval of Cobenfy for the treatment of schizophrenia.
6 of Wall Street's Most Beloved High-Yield Stocks Are On Sale
Key Points Yields have drifted higher since the Federal Reserve cut rates in September.
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case.
2 Beaten-Down Dividend Stocks to Buy and Hold
They're down, but they aren't out, at least not in the eyes of patient investors.
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink Partners has upgraded Bristol-Myers Squibb & Co BMY, stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy (a schizophrenia drug) and milvexian (anticoagulant).
Buy, Sell, Or Hold BMY Stock?
Bristol Myers Squibb stock (NYSE: BMY) was up 10% on Monday, November 11, after its peer AbbVie (NYSE; ABBV) announced that two of its mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. [1] Emraclidine was developed by Cerevel Therapeutics, which AbbVie acquired for around $9 billion earlier this year.
